Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Net Margin (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Net Margin for 4 consecutive years, with 349.3% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin fell 26417.0% to 349.3% in Q3 2025 year-over-year; TTM through Sep 2025 was 217.5%, a 12734.0% decrease, with the full-year FY2024 number at 96.56%, up 21685.0% from a year prior.
  • Net Margin was 349.3% for Q3 2025 at bioAffinity Technologies, down from 319.88% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 22.05% in Q2 2022 to a low of 427778.96% in Q3 2022.
  • A 4-year average of 48318.34% and a median of 231.7% in 2025 define the central range for Net Margin.
  • Biggest YoY gain for Net Margin was 42701145bps in 2023; the steepest drop was -883841bps in 2023.
  • bioAffinity Technologies' Net Margin stood at 71380.35% in 2022, then soared by 100bps to 107.22% in 2023, then dropped by -25bps to 134.4% in 2024, then crashed by -160bps to 349.3% in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Net Margin are 349.3% (Q3 2025), 319.88% (Q2 2025), and 143.53% (Q1 2025).